patent cliffs

Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Fierce Pharma
M&A
patent cliffs
Merck
JNJ
Pfizer
GSK
Novartis
Eli Lilly
Novo Nordisk
Flag link:
BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's
BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's
Fierce Pharma
Pfizer
Merck
Bristol Myers Squibb
patents
patent cliffs
M&A
Flag link:
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Flag link:
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Fierce Pharma
patents
patent cliffs
Bristol Myers Squibb
Amgen
Pfizer
Revlimid
Eliquis
Enbrel
Otezla
Ibrance
Flag link:
Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space
Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space
TheStreet.com
drug pricing
patents
patent cliffs
M&A
generics
Flag link:
Pharma Starts a Feedback Loop
Pharma Starts a Feedback Loop
Drug Patent Watch
patents
generics
patent expirations
patent cliffs
innovation
drug development
Flag link: